acoltremon · Alcon Labs Inc · NDA 217370
Tryptyr
Earliest generic entry, as listed
16 Dec 2042
Blocked by patent: US 11850221, US 12336971.
Listed patents · 5 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11850221 | product, use U-1900 | 16 Dec 2042 |
| US 12336971 | use U-1900 | 16 Dec 2042 |
| US 10028920 | use U-1900 | 8 Sep 2031 |
| US 9095609 | product, use U-1900 | 8 Sep 2031 |
| US 9433679 | use U-1900 | 8 Sep 2031 |
Exclusivities · 1 unexpired
| NCE | new chemical entity (5 years) | 28 May 2030 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 217370 · 001 · RLD | solution/drops, ophthalmic | 0.003% | 16 Dec 2042 |